Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a research note issued on Monday. The firm set a “sell” rating on the stock.

Oragenics Price Performance

NYSE:OGEN opened at $0.18 on Monday. The business has a 50 day simple moving average of $0.24 and a 200-day simple moving average of $0.30. The firm has a market capitalization of $3.76 million, a price-to-earnings ratio of -0.02 and a beta of 0.87. Oragenics has a 1 year low of $0.16 and a 1 year high of $3.43.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.